Literature DB >> 16050512

Serological evidence for the co-circulation of multiple dengue virus serotypes in Singapore.

Annelies Wilder-Smith1, Sutee Yoksan, Arul Earnest, Ravathi Subramaniam, Nicholas I Paton.   

Abstract

We did a seroepidemiological study to determine the circulating dengue virus serotypes and the extent to which the Singapore population has been exposed to multiple dengue virus serotypes, using the plaque reduction neutralization assay (PRNT). Of 164 enrolled subjects aged between 18-30 years, 49 subjects (29.8%) were PRNT positive for at least one dengue serotype. The seroprevalence was 39 (23.8%) for dengue virus serotype 1, 37 (22.6%) for type 2, 43 (26.2%) for type 3, and 30 (18.3%) for type 4. Of the 49 subjects with PRNT-positive dengue virus results, 28 (57.1%) were positive to all four virus serotypes, seven (14.3%) to three serotypes, two (4%) to two serotypes, and 12 (24.5%) to a single serotype. All four dengue virus serotypes circulate in Singapore, and a substantial proportion of the adult population in Singapore had exposure to more than one dengue virus serotype. In spite of multiple circulating types, the rate of dengue haemorrhagic fever is low in Singapore.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16050512      PMCID: PMC2870294          DOI: 10.1017/s0950268805003821

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  18 in total

1.  Forty Years of Dengue Surveillance at a Tertiary Pediatric Hospital in Bangkok, Thailand, 1973-2012.

Authors:  Ananda Nisalak; Hannah E Clapham; Siripen Kalayanarooj; Chonticha Klungthong; Butsaya Thaisomboonsuk; Stefan Fernandez; Julia Reiser; Anon Srikiatkhachorn; Louis R Macareo; Justin T Lessler; Derek A T Cummings; In-Kyu Yoon
Journal:  Am J Trop Med Hyg       Date:  2016-03-28       Impact factor: 2.345

2.  Dengue infections in non-immune travellers to Thailand.

Authors:  E Massad; J Rocklov; A Wilder-Smith
Journal:  Epidemiol Infect       Date:  2012-04-24       Impact factor: 4.434

3.  Occurrence of co-infection with dengue viruses during 2014 in New Delhi, India.

Authors:  A Tazeen; N Afreen; M Abdullah; F Deeba; S H Haider; S N Kazim; S Ali; I H Naqvi; S Broor; A Ahmed; S Parveen
Journal:  Epidemiol Infect       Date:  2016-09-13       Impact factor: 4.434

4.  Age-specificity of clinical dengue during primary and secondary infections.

Authors:  Khoa T D Thai; Hiroshi Nishiura; Phuong Lan Hoang; Nga Thanh Thi Tran; Giao Trong Phan; Hung Quoc Le; Binh Quang Tran; Nam Van Nguyen; Peter J de Vries
Journal:  PLoS Negl Trop Dis       Date:  2011-06-21

Review 5.  Dengue prevention and 35 years of vector control in Singapore.

Authors:  Eng-Eong Ooi; Kee-Tai Goh; Duane J Gubler
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

6.  Force of infection of dengue serotypes in a population-based study in the northeast of Brazil.

Authors:  P M S Castanha; M T Cordeiro; C M T Martelli; W V Souza; E T A Marques; C Braga
Journal:  Epidemiol Infect       Date:  2012-07-17       Impact factor: 4.434

7.  Dengue seroprevalence of healthy adults in Singapore: serosurvey among blood donors, 2009.

Authors:  Swee-Ling Low; Sally Lam; Wing-Yan Wong; Diana Teo; Lee-Ching Ng; Li-Kiang Tan
Journal:  Am J Trop Med Hyg       Date:  2015-05-26       Impact factor: 2.345

8.  Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISA.

Authors:  Petra Emmerich; Angela Mika; Herbert Schmitz
Journal:  PLoS Negl Trop Dis       Date:  2013-12-26

9.  Clinical findings and pro-inflammatory cytokines in dengue patients in Western India: a facility-based study.

Authors:  D Priyadarshini; Rajesh R Gadia; Anuradha Tripathy; K R Gurukumar; Asha Bhagat; Sampada Patwardhan; Nitin Mokashi; Dhananjay Vaidya; Paresh S Shah; D Cecilia
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

10.  Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].

Authors:  Katherine L Williams; Soila Sukupolvi-Petty; Martina Beltramello; Syd Johnson; Federica Sallusto; Antonio Lanzavecchia; Michael S Diamond; Eva Harris
Journal:  PLoS Pathog       Date:  2013-02-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.